Pfizer, Inc.

Equities

PFE

US7170811035

Pharmaceuticals

Market Closed - Nyse 04:00:39 2024-03-01 pm EST 5-day change 1st Jan Change
26.59 USD +0.11% Intraday chart for Pfizer, Inc. -4.21% -7.64%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
US judge upholds Medicare drug price negotiation program RE
Pfizer: eight oncology blockbusters expected by 2030 CF
PFIZER INC : JP Morgan sticks Neutral ZD
Wall Street: a flurry of records, including that of the Nasdaq 'broad CF
Wall Street: a flurry of records, including that of the Nasdaq 'large'. CF
Transcript : Pfizer Inc. - Special Call
European Midday Briefing : Caution Ahead of Key U.S. Inflation Print Keeps Stocks in Check DJ
Haleon Backs Views After Profit Rise on Robust Growth -- Update DJ
Haleon Backs Views After Profit Rise on Robust Growth DJ
Novavax sees 2024 sales flat to lower, aims to pick up COVID vaccine market share RE
Drugmakers deepen efforts to tap into booming market for obesity drugs RE
Guggenheim Initiates Pfizer With Buy Rating, Price Target is $36 MT
Prices for new US drugs rose 35% in 2023, more than the previous year RE
Moderna CEO: 'Excited' About Future Following 4Q Revenue MT
Moderna reports surprise profit, sets out road map for RSV vaccine RE
Everest Medicines' Partner Pfizer Announces European Commission Approves VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis CI
ViiV Says Trial Data Shows Injectable HIV Treatment Cabenuva Has 'Superior Efficacy' Compared With Pills in Some People MT
GSK: 'remarkable' results in HIV treatment CF
ViiV's Long-acting Injectable HIV Drug Shown More Effective than Daily Pills in Phase 3 Study MT
Amazon replaces Walgreens on Dow Jones index RE
China move leaves markets unfazed Our Logo
Pfizer Receives EU Marketing Authorization for Ulcerative Colitis Treatment MT
Pfizer Receives EU Marketing Approval for Ulcerative Colitis Therapy MT
Pfizer: EU green light for treatment of ulcerative colitis CF
Pfizer inflammatory bowel disease drug wins EU approval RE
Chart Pfizer, Inc.
More charts
Pfizer, Inc. is the world's leading pharmaceutical group. Net sales break down by family of products as follows: - primary care products (72.8%): medicines used in internal medicine, vaccines, medicines for the prevention and treatment of Covid-19, antivirals, mRNA-based products, etc.; - specialty care products (13.8%): medicines used in immunology, in hospitals and for the treatment of rare diseases, anti-inflammatory medicines, etc.; - oncology products (12.1%); - other (1.3%). At the end of 2022, the group had more than 35 manufacturing sites worldwide. Net sales are distributed geographically as follows: the United States (42.3%), Europe (21.9%) and other (35.8%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
26.59 USD
Average target price
32.71 USD
Spread / Average Target
+23.03%
Consensus
  1. Stock
  2. Equities
  3. Stock Pfizer, Inc. - Nyse
  4. News Pfizer, Inc.
  5. Powell's Comments on Interest-Rate Hikes Leave Equities Modestly Higher Friday Afternoon
-40% Limited-time offer: Our subscriptions help you unlock the best investment opportunities.
SIGN UP NOW